109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
单独间歇性禁食或间歇性禁食联合胰高血糖素样肽 - 1 受体激动剂对非酒精性脂肪肝大鼠的蛋白质组学分析
Authors Shao Y , Xu S , Ma Y , Zhang J, Guo X, Zhang T , Yuan G
Received 17 July 2025
Accepted for publication 29 October 2025
Published 5 November 2025 Volume 2025:18 Pages 4073—4083
DOI https://doi.org/10.2147/DMSO.S550262
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Jae Woong Sull
Yimin Shao,1 Shengya Xu,1 Yuanyuan Ma,2 Junqing Zhang,1 Xiaohui Guo,1 Tingting Zhang,1 Geheng Yuan1
1Department of Endocrinology, Peking University First Hospital, Beijing, People’s Republic of China; 2Laboratory Animal Center, Peking University First Hospital, Beijing, People’s Republic of China
Correspondence: Tingting Zhang, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86 10 83575103, Fax +86 10 66552395, Email cathine@sina.com Geheng Yuan, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86 10 83575103, Fax +86 10 66552395, Email 139197109@qq.com
Background: Intermittent fasting (IF) and glucagon-like peptide-1 receptor agonists (GLP-1RA) offer effective therapeutic options for nonalcoholic fatty liver disease (NAFLD). This study aimed to examine the effects of alternate-day fasting (ADF) alone and with liraglutide, and to explore the mechanisms behind each treatment.
Methods: To establish the model for NAFLD, Sprague-Dawley rats were given a high-fat diet for 25 weeks. Subsequently, the rats were assigned to the ADF, ADF combined with liraglutide (A+L), and control groups for an additional 5 weeks. Evaluations were performed on liver morphology, body weight, serum lipid profiles, insulin sensitivity, and liver proteomics.
Results: Compared to the control group, ADF alone demonstrated a reduction in body weight (37.1± 15.56 g vs − 20.68± 15.58 g, p< 0.05), food intake (0.30± 0.002 g/d/rat vs 0.18± 6.21 g/d/rat), blood lipid levels, and ALT concentration (139.0± 15.57 U/L vs 91.25± 41.9 U/L, p< 0.05), while also improving the NAFLD score. Furthermore, ADF in conjunction with liraglutide exhibited superior effects in reducing body weight (− 96.15± 15.78 g), food intake (− 10.25± 0.01 g/d/rat), triglyceride (17.53± 0.25 nmol/L), and LDL concentrations (6.93± 0.35mmol/L), as well as ameliorating insulin resistance and lowering the NAFLD score relative to the ADF group (p< 0.05). The proteomic analysis indicates that G protein-coupled receptor 39 (GPR39) and transmembrane protein 41b (Tmem41b) were significantly upregulated in the A+L group compared to the other two groups. Additionally, hydroxysteroid 17β-dehydrogenase 2 (HSD17B2) was significantly diminished in both the ADF and A+L groups relative to the control group.
Conclusion: Intermittent fasting, in conjunction with GLP-1RA, further enhances metabolic health in individuals with NAFLD as a result of obesity. This study provides support for forthcoming clinical trials and aims to establish new therapeutic targets in the context of NAFLD.
Keywords: intermittent fasting, non-alcoholic fatty liver disease, glucagon-like peptide-1, proteomic changes, obesity
1Department of Endocrinology, Peking University First Hospital, Beijing, People’s Republic of China; 2Laboratory Animal Center, Peking University First Hospital, Beijing, People’s Republic of China
Correspondence: Tingting Zhang, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86 10 83575103, Fax +86 10 66552395, Email cathine@sina.com Geheng Yuan, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86 10 83575103, Fax +86 10 66552395, Email 139197109@qq.com
Background: Intermittent fasting (IF) and glucagon-like peptide-1 receptor agonists (GLP-1RA) offer effective therapeutic options for nonalcoholic fatty liver disease (NAFLD). This study aimed to examine the effects of alternate-day fasting (ADF) alone and with liraglutide, and to explore the mechanisms behind each treatment.
Methods: To establish the model for NAFLD, Sprague-Dawley rats were given a high-fat diet for 25 weeks. Subsequently, the rats were assigned to the ADF, ADF combined with liraglutide (A+L), and control groups for an additional 5 weeks. Evaluations were performed on liver morphology, body weight, serum lipid profiles, insulin sensitivity, and liver proteomics.
Results: Compared to the control group, ADF alone demonstrated a reduction in body weight (37.1± 15.56 g vs − 20.68± 15.58 g, p< 0.05), food intake (0.30± 0.002 g/d/rat vs 0.18± 6.21 g/d/rat), blood lipid levels, and ALT concentration (139.0± 15.57 U/L vs 91.25± 41.9 U/L, p< 0.05), while also improving the NAFLD score. Furthermore, ADF in conjunction with liraglutide exhibited superior effects in reducing body weight (− 96.15± 15.78 g), food intake (− 10.25± 0.01 g/d/rat), triglyceride (17.53± 0.25 nmol/L), and LDL concentrations (6.93± 0.35mmol/L), as well as ameliorating insulin resistance and lowering the NAFLD score relative to the ADF group (p< 0.05). The proteomic analysis indicates that G protein-coupled receptor 39 (GPR39) and transmembrane protein 41b (Tmem41b) were significantly upregulated in the A+L group compared to the other two groups. Additionally, hydroxysteroid 17β-dehydrogenase 2 (HSD17B2) was significantly diminished in both the ADF and A+L groups relative to the control group.
Conclusion: Intermittent fasting, in conjunction with GLP-1RA, further enhances metabolic health in individuals with NAFLD as a result of obesity. This study provides support for forthcoming clinical trials and aims to establish new therapeutic targets in the context of NAFLD.
Keywords: intermittent fasting, non-alcoholic fatty liver disease, glucagon-like peptide-1, proteomic changes, obesity